1.59

4.79% -0.08

Pre-market: 1.61 0.02 +1.26%

Revelation Biosciences Inc (REVB)

Overview News Price History Financials Discussions Forecast Stock Split

Revelation Biosciences Inc stock is traded at $1.59, with a volume of 964.84K. It is down -4.79% in the last 24 hours and down -51.12% over the past month. Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Previous Close:

$1.67

Open:

$1.76

24h Volume:

964.84K

Relative Volume:

1.82

Market Cap:

$4.17M

Revenue:

Net Income/Loss:

$-15.52M

P/E Ratio:

-0.0856

EPS:

-18.58

Net Cash Flow:

$-16.61M

1W Performance:

-23.92%

1M Performance:

-51.12%

6M Performance:

-84.35%

1Y Performance:

-91.09%

1-Day Range:

$1.5766

$1.86

1-Week Range:

$1.5766

$2.13

52-Week Range:

$1.5766

$18.32

Revelation Biosciences Inc Stock (REVB) Company Profile

Name

Revelation Biosciences Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

650-800-3717

Address

4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

REVB's Discussions on Twitter

Compare REVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REVB Revelation Biosciences Inc	1.59	4.38M	0	-15.52M	-16.61M	-18.58
VRTX Vertex Pharmaceuticals Inc	470.52	118.13B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	775.06	79.79B	14.34B	4.50B	3.88B	41.57
ARGX Argen X Se Adr	850.87	52.71B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	351.96	46.48B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	352.00	38.33B	4.98B	69.60M	525.67M	0.5198

Revelation Biosciences Inc Stock (REVB) Latest News

Feb 03, 2026

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Victorville Daily Press

Feb 03, 2026

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - The News-Star

Feb 03, 2026

Feb 02, 2026

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - El Paso Times

Feb 02, 2026

Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - Lebanon Daily News

Feb 02, 2026

Feb 01, 2026

Fundamentals Check: What is Graf Global Corp Debt Equity Composite Unitss valuation compared to sectorJuly 2025 Breakouts & AI Driven Price Forecasts - baoquankhu1.vn

Feb 01, 2026

Buyback Watch: Is ETHE trading at a discountJuly 2025 Market Mood & Expert Verified Stock Movement Alerts - baoquankhu1.vn

Feb 01, 2026

Jan 29, 2026

Can Revelation Biosciences Inc. expand into new marketsPortfolio Value Report & Daily Market Momentum Tracking - mfd.ru

Jan 29, 2026

Is Revelation Biosciences Inc. Equity Warrant backed by strong institutional buyingWeekly Market Summary & Weekly Return Optimization Alerts - mfd.ru

Jan 29, 2026

Revelation Biosciences Raises Capital via Warrant Inducement - TipRanks

Jan 29, 2026

Revelation Biosciences Signs Multiple Material Agreements - TradingView

Jan 29, 2026

Jan 28, 2026

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 - Chronicle-Tribune

Jan 28, 2026

US Market Recap: Whats the beta of Revelation Biosciences Inc stock2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Jan 28, 2026

Jan 27, 2026

REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year - Asianet Newsable

Jan 27, 2026

Revelation Biosciences to implement 1-for-4 reverse stock split By Investing.com - Investing.com Nigeria

Jan 27, 2026

Jan 26, 2026

Revelation Biosciences to Implement 1-for-4 Reverse Stock Split - marketscreener.com

Jan 26, 2026

Revelation Biosciences to implement 1-for-4 reverse stock split - Investing.com

Jan 26, 2026

Revelation Biosciences to combine 4 shares into 1 for Nasdaq bid - Stock Titan

Jan 26, 2026

Jan 24, 2026

Revelation Biosciences announces warrant exercise agreement By Investing.com - Investing.com Australia

Jan 24, 2026

Jan 23, 2026